Intravenous immunoglobulin for treatment of hospitalized COVID-19 patients: an evidence mapping and meta-analysis

被引:0
作者
Mei-xuan Li
Yan-fei Li
Xin Xing
Jun-qiang Niu
Liang Yao
Meng-ying Lu
Ke Guo
Mi-na Ma
Xiao-tian Wu
Ning Ma
Dan Li
Zi-jun Li
Ling Guan
Xiao-man Wang
Bei Pan
Wen-ru Shang
Jing Ji
Zhong-yang Song
Zhi-ming Zhang
Yong-feng Wang
Ke-hu Yang
机构
[1] Lanzhou University,Evidence
[2] Lanzhou University,Based Medicine Center, School of Basic Medical Sciences
[3] Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province,Evidence
[4] Lanzhou University,Based Social Science Research Center, Health Technology Assessment Center, School of Public Health
[5] Gansu University of Chinese Medicine,WHO Collaborating Centre for Guideline Implementation and Knowledge Translation
[6] The First Hospital of Lanzhou University,School of Public Health
[7] McMaster University,Department of Traditional Chinese Medicine
[8] Lanzhou University,Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences
[9] Lanzhou University,The First School of Clinical Medicine
[10] Gansu Provincial Hospital of Traditional Chinese Medicine,School/Hospital of Stomatology
[11] Affiliated Hospital of Gansu University of Chinese Medicine,Department of Rehabilitation
[12] Gansu Medical College,undefined
来源
Inflammopharmacology | 2024年 / 32卷
关键词
COVID-19; Intravenous immunoglobulin; Efficacy; Safety; Evidence mapping; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:335 / 354
页数:19
相关论文
共 224 条
[21]  
Ma Z(2020)Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis PLoS Med 20 204-undefined
[22]  
Zhang Y(2021)COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review) Iran J Microbiol 14 1538-undefined
[23]  
Lin L(2022)The effect of intravenous immunoglobulins on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials Expert Rev Anti Infect Ther 27 19-undefined
[24]  
Chen Y(2023)Use of traditional Chinese medicine for the treatment and prevention of COVID-19 and rehabilitation of COVID-19 patients: an evidence mapping study Front Pharmacol 32 S166-undefined
[25]  
Xie J(2021)Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study Clin Microbiol Infect 10 18-undefined
[26]  
Wu W(2022)Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID-19 patients: a systematic review and meta-analysis Rev Med Virol 372 603-undefined
[27]  
Li S(2022)Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial Lancet Respir Med 130 38-undefined
[28]  
Hu Y(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 26 163-undefined
[29]  
Hu M(2020)Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis Pol Arch Intern Med 223 undefined-undefined
[30]  
Chen L(2022)Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study Crit Care 22 undefined-undefined